Neon Therapeutics, a Cambridge, MA-based newly formed immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, raised $55m Series A financing.
The round was led by Third Rock Ventures, LLC, with participation from Clal Biotechnology Industries and Access Industries.
Led by Cary Pfeffer, M.D., interim chief executive officer, and Robert Tepper, M.D., interim chief scientific officer, Neon Therapeutics is advancing NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials developed collaboratively by the Broad Institute and Dana-Farber Cancer Institute under the leadership of Dr. Catherine Wu, and philanthropically funded in part by the Blavatnik Family Foundation.
The company will also develop personalized T cell therapies.
Founders of Neon include:
– James Allison, Ph.D., MD Anderson Cancer Center
– Ed Fritsch, Ph.D., Neon Therapeutics
– Nir Hacohen, Ph.D., Broad Institute and Massachusetts General Hospital
– Eric Lander, Ph.D., Broad Institute of MIT and Harvard
– Robert Schreiber, Ph.D., Washington University
– Ton Schumacher, Ph.D., Netherlands Cancer Institute
– Catherine Wu, M.D., Broad Institute and Dana-Farber Cancer Institute.